[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fny904zf53lAkB6sLw9wq2hG2FAmVkCxipjRvRryS40Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":61,"rows":68},"NHS Greater Glasgow and Clyde",[4],217,false,31,9,161204,7,177,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Heart Failure",14,{"name":18,"count":19},"Stroke",13,{"name":21,"count":22},"Cardiovascular Diseases",10,{"name":24,"count":25},"Rheumatoid Arthritis",6,{"name":27,"count":25},"Obesity",{"name":29,"count":30},"Crohn Disease",5,{"name":32,"count":30},"Insomnia",{"name":34,"count":30},"Spinal Cord Injuries",[36,41,46,51,56],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06784076","Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue","2025-03-17","Anifrolumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06821347","NanO2 in Large VessEL Occlusion Stroke (NOVEL)","2026-07-31","NanO2TM",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05179499","Early Vasopressors in Sepsis","2026-11","Norepinephrine",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06786936","Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms","2027-02-28","Secukinumab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07443956","Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","2028-02","Ixekizumab",[62,63,64,65,66,67],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[69,94,116,152,170,188,206,227,264,289,311,336,361,386,411,435,461,486,511,556,583,601,626,644,673,699,717,752,777,802,820,838,856,874,892,910,935,958,987,1005,1030,1064,1090,1117,1135,1153,1176,1200,1224,1248,1266],{"intervention":50,"totalTrials":70,"cells":71},1,{"EARLY_PHASE1":72,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":90,"NA":92},{"trials":73,"activeCount":74},[],0,{"trials":76,"activeCount":74},[],{"trials":78,"activeCount":74},[],{"trials":80,"activeCount":70,"soonestReadout":49},[81],{"nctId":47,"briefTitle":48,"status":82,"phases":83,"primaryCompletion":49,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":89},"RECRUITING",[65],"2027-10","2022-10-11",1006,[88],"Sepsis",[50],{"trials":91,"activeCount":74},[],{"trials":93,"activeCount":74},[],{"intervention":45,"totalTrials":70,"cells":95},{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":110,"PHASE4":112,"NA":114},{"trials":97,"activeCount":74},[],{"trials":99,"activeCount":74},[],{"trials":101,"activeCount":70,"soonestReadout":44},[102],{"nctId":42,"briefTitle":43,"status":103,"phases":104,"primaryCompletion":44,"completion":44,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NOT_YET_RECRUITING",[64],"2025-05-01",172,[108],"Stroke Acute",[45],{"trials":111,"activeCount":74},[],{"trials":113,"activeCount":74},[],{"trials":115,"activeCount":74},[],{"intervention":60,"totalTrials":117,"cells":118},2,{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":129},{"trials":120,"activeCount":74},[],{"trials":122,"activeCount":74},[],{"trials":124,"activeCount":74},[],{"trials":126,"activeCount":74},[],{"trials":128,"activeCount":74},[],{"trials":130,"activeCount":117,"soonestReadout":54},[131,142],{"nctId":52,"briefTitle":53,"status":82,"phases":132,"primaryCompletion":54,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":140},[],"2027-04-30","2025-06-02",50,[137,138,139],"Psoriatic Arthritis","Depression","Psoriatic Plaque",[55,141,60],"Bimekizumab",{"nctId":57,"briefTitle":58,"status":82,"phases":143,"primaryCompletion":59,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":150},[67],"2030-05","2026-03-09",45,[148,149],"Psoriatic Arthritis (PsA)","Obesity & Overweight",[60,151],"Tirzepatide",{"intervention":55,"totalTrials":70,"cells":153},{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":164},{"trials":155,"activeCount":74},[],{"trials":157,"activeCount":74},[],{"trials":159,"activeCount":74},[],{"trials":161,"activeCount":74},[],{"trials":163,"activeCount":74},[],{"trials":165,"activeCount":70,"soonestReadout":54},[166],{"nctId":52,"briefTitle":53,"status":82,"phases":167,"primaryCompletion":54,"completion":133,"start":134,"enrollment":135,"conditions":168,"interventions":169},[],[137,138,139],[55,141,60],{"intervention":141,"totalTrials":70,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":182},{"trials":173,"activeCount":74},[],{"trials":175,"activeCount":74},[],{"trials":177,"activeCount":74},[],{"trials":179,"activeCount":74},[],{"trials":181,"activeCount":74},[],{"trials":183,"activeCount":70,"soonestReadout":54},[184],{"nctId":52,"briefTitle":53,"status":82,"phases":185,"primaryCompletion":54,"completion":133,"start":134,"enrollment":135,"conditions":186,"interventions":187},[],[137,138,139],[55,141,60],{"intervention":151,"totalTrials":70,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":200},{"trials":191,"activeCount":74},[],{"trials":193,"activeCount":74},[],{"trials":195,"activeCount":74},[],{"trials":197,"activeCount":74},[],{"trials":199,"activeCount":74},[],{"trials":201,"activeCount":70,"soonestReadout":59},[202],{"nctId":57,"briefTitle":58,"status":82,"phases":203,"primaryCompletion":59,"completion":144,"start":145,"enrollment":146,"conditions":204,"interventions":205},[67],[148,149],[60,151],{"intervention":40,"totalTrials":70,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":218},{"trials":209,"activeCount":74},[],{"trials":211,"activeCount":74},[],{"trials":213,"activeCount":74},[],{"trials":215,"activeCount":74},[],{"trials":217,"activeCount":74},[],{"trials":219,"activeCount":70,"soonestReadout":39},[220],{"nctId":37,"briefTitle":38,"status":103,"phases":221,"primaryCompletion":39,"completion":222,"start":39,"enrollment":223,"conditions":224,"interventions":226},[],"2027-03-15",20,[225],"Systemic Lupus Erythematosus",[40],{"intervention":228,"totalTrials":117,"cells":229},"Empagliflozin 10 MG",{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":249,"NA":262},{"trials":231,"activeCount":74},[],{"trials":233,"activeCount":74},[],{"trials":235,"activeCount":74},[],{"trials":237,"activeCount":74},[238],{"nctId":239,"briefTitle":240,"status":241,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":248},"NCT05020704","EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction","UNKNOWN",[65],"2024-06-12","2022-09-16",100,[247],"Myocardial Infarction",[228],{"trials":250,"activeCount":74},[251],{"nctId":252,"briefTitle":253,"status":254,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT03485092","Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects","COMPLETED",[66],"2020-03-28","2018-03-16",105,[15,260],"Diabetes Mellitus",[228],{"trials":263,"activeCount":74},[],{"intervention":265,"totalTrials":70,"cells":266},"Allopurinol",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":287},{"trials":268,"activeCount":74},[],{"trials":270,"activeCount":74},[],{"trials":272,"activeCount":74},[],{"trials":274,"activeCount":74},[],{"trials":276,"activeCount":74},[277],{"nctId":278,"briefTitle":279,"status":254,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":286},"NCT02122718","XILO-FIST, the Effect of Allopurinol on the Brain Heart and Blood Pressure After Stroke",[66],"2021-02","2014-05",464,[285],"Ischaemic Stroke",[265],{"trials":288,"activeCount":74},[],{"intervention":290,"totalTrials":70,"cells":291},"Eplerenone",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":300,"NA":309},{"trials":293,"activeCount":74},[],{"trials":295,"activeCount":74},[],{"trials":297,"activeCount":74},[],{"trials":299,"activeCount":74},[],{"trials":301,"activeCount":74},[302],{"nctId":303,"briefTitle":304,"status":254,"phases":305,"start":306,"enrollment":245,"conditions":307,"interventions":308},"NCT00132093","Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack",[66],"2005-04",[247],[290],{"trials":310,"activeCount":74},[],{"intervention":312,"totalTrials":70,"cells":313},"Abatacept",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":322,"NA":334},{"trials":315,"activeCount":74},[],{"trials":317,"activeCount":74},[],{"trials":319,"activeCount":74},[],{"trials":321,"activeCount":74},[],{"trials":323,"activeCount":74},[324],{"nctId":325,"briefTitle":326,"status":241,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT02652273","Inhibition of Co-Stimulation in Rheumatoid Arthritis",[66],"2019-01","2016-01",25,[332],"Arthritis, Rheumatoid",[312],{"trials":335,"activeCount":74},[],{"intervention":337,"totalTrials":70,"cells":338},"Torasemide 5Mg",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":359},{"trials":340,"activeCount":74},[],{"trials":342,"activeCount":74},[],{"trials":344,"activeCount":74},[],{"trials":346,"activeCount":74},[],{"trials":348,"activeCount":74},[349],{"nctId":350,"briefTitle":351,"status":254,"phases":352,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":358},"NCT03354897","Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension",[66],"2021-10-30","2017-04-05",228,[21,357],"Hypertension",[337],{"trials":360,"activeCount":74},[],{"intervention":362,"totalTrials":70,"cells":363},"Inhaled Tiotropium",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":384},{"trials":365,"activeCount":74},[],{"trials":367,"activeCount":74},[],{"trials":369,"activeCount":74},[],{"trials":371,"activeCount":74},[],{"trials":373,"activeCount":74},[374],{"nctId":375,"briefTitle":376,"status":377,"phases":378,"completion":379,"start":380,"enrollment":146,"conditions":381,"interventions":383},"NCT00335621","Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)","WITHDRAWN",[66],"2007-12","2006-06",[382],"Chronic Obstructive Pulmonary Disease",[362],{"trials":385,"activeCount":74},[],{"intervention":387,"totalTrials":70,"cells":388},"Levobupivacaine",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":409},{"trials":390,"activeCount":74},[],{"trials":392,"activeCount":74},[],{"trials":394,"activeCount":74},[],{"trials":396,"activeCount":74},[],{"trials":398,"activeCount":74},[399],{"nctId":400,"briefTitle":401,"status":241,"phases":402,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":408},"NCT00926666","A Dose Finding Study for Pain Relief of a Broken Hip",[66],"2011-04","2009-10",48,[407],"Femoral Neck Fractures",[387],{"trials":410,"activeCount":74},[],{"intervention":412,"totalTrials":70,"cells":413},"Levothyroxine",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":433},{"trials":415,"activeCount":74},[],{"trials":417,"activeCount":74},[],{"trials":419,"activeCount":74},[],{"trials":421,"activeCount":74},[],{"trials":423,"activeCount":74},[424],{"nctId":425,"briefTitle":426,"status":254,"phases":427,"primaryCompletion":428,"completion":428,"start":282,"enrollment":429,"conditions":430,"interventions":432},"NCT01660126","Thyroid Hormone Replacement for Subclinical Hypothyroidism",[66],"2016-11-18",737,[431],"Subclinical Hypothyroidism",[412],{"trials":434,"activeCount":74},[],{"intervention":436,"totalTrials":70,"cells":437},"Patiromer",{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":459},{"trials":439,"activeCount":74},[],{"trials":441,"activeCount":74},[],{"trials":443,"activeCount":74},[],{"trials":445,"activeCount":74},[],{"trials":447,"activeCount":74},[448],{"nctId":449,"briefTitle":450,"status":451,"phases":452,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":458},"NCT04142788","RELieving Increasing oEdema Due to Heart Failure","TERMINATED",[66],"2022-12-20","2020-08-26",19,[457],"Heart Failure，Congestive",[436],{"trials":460,"activeCount":74},[],{"intervention":462,"totalTrials":70,"cells":463},"Prednisolone",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":484},{"trials":465,"activeCount":74},[],{"trials":467,"activeCount":74},[],{"trials":469,"activeCount":74},[],{"trials":471,"activeCount":74},[],{"trials":473,"activeCount":74},[474],{"nctId":475,"briefTitle":476,"status":254,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":483},"NCT03610685","Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma",[66],"2020-01-07","2018-10-19",33,[482],"Asthma",[462],{"trials":485,"activeCount":74},[],{"intervention":487,"totalTrials":70,"cells":488},"Benralizumab",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":509},{"trials":490,"activeCount":74},[],{"trials":492,"activeCount":74},[],{"trials":494,"activeCount":74},[],{"trials":496,"activeCount":74},[],{"trials":498,"activeCount":74},[499],{"nctId":500,"briefTitle":501,"status":254,"phases":502,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":508},"NCT04102800","Benralizumab Exacerbation Study",[66],"2024-02-22","2024-04-23","2019-09-30",157,[482],[487],{"trials":510,"activeCount":74},[],{"intervention":512,"totalTrials":117,"cells":513},"Carboplatin",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":537,"PHASE4":552,"NA":554},{"trials":515,"activeCount":74},[],{"trials":517,"activeCount":74},[],{"trials":519,"activeCount":74},[520],{"nctId":521,"briefTitle":522,"status":241,"phases":523,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":531},"NCT02866370","Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium",[64],"2020-03","2021-03","2015-04",120,[529,530],"Ovarian Clear Cell Carcinoma","Endometrial Clear Cell Carcinoma",[532,533,534,535,512,536],"Nintedanib","Paclitaxel","Pegylated Liposomal Doxorubicin","Topotecan","Doxorubicin",{"trials":538,"activeCount":74},[539],{"nctId":540,"briefTitle":541,"status":254,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":550},"NCT00098878","Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[65],"2010-07","2004-03",1300,[547,548,549],"Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cavity Cancer",[551],"carboplatin",{"trials":553,"activeCount":74},[],{"trials":555,"activeCount":74},[],{"intervention":557,"totalTrials":70,"cells":558},"Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":579,"NA":581},{"trials":560,"activeCount":74},[],{"trials":562,"activeCount":74},[],{"trials":564,"activeCount":74},[],{"trials":566,"activeCount":74},[567],{"nctId":568,"briefTitle":569,"status":254,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":577},"NCT02814409","Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis",[65],"2023-08-31","2024-01-10","2016-12-15",1858,[576],"Ischemic Stroke",[557,578],"Intravenous Tenecteplase",{"trials":580,"activeCount":74},[],{"trials":582,"activeCount":74},[],{"intervention":578,"totalTrials":70,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":597,"NA":599},{"trials":586,"activeCount":74},[],{"trials":588,"activeCount":74},[],{"trials":590,"activeCount":74},[],{"trials":592,"activeCount":74},[593],{"nctId":568,"briefTitle":569,"status":254,"phases":594,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":595,"interventions":596},[65],[576],[557,578],{"trials":598,"activeCount":74},[],{"trials":600,"activeCount":74},[],{"intervention":602,"totalTrials":70,"cells":603},"sacubitril\u002Fvalsartan",{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":622,"NA":624},{"trials":605,"activeCount":74},[],{"trials":607,"activeCount":74},[],{"trials":609,"activeCount":74},[],{"trials":611,"activeCount":74},[612],{"nctId":613,"briefTitle":614,"status":254,"phases":615,"primaryCompletion":616,"completion":616,"start":617,"enrollment":618,"conditions":619,"interventions":620},"NCT03552575","The Effects of Sacubitril\u002FValsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI",[65],"2020-07-25","2018-07-01",93,[15],[602,621],"Valsartan",{"trials":623,"activeCount":74},[],{"trials":625,"activeCount":74},[],{"intervention":621,"totalTrials":70,"cells":627},{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":634,"PHASE4":640,"NA":642},{"trials":629,"activeCount":74},[],{"trials":631,"activeCount":74},[],{"trials":633,"activeCount":74},[],{"trials":635,"activeCount":74},[636],{"nctId":613,"briefTitle":614,"status":254,"phases":637,"primaryCompletion":616,"completion":616,"start":617,"enrollment":618,"conditions":638,"interventions":639},[65],[15],[602,621],{"trials":641,"activeCount":74},[],{"trials":643,"activeCount":74},[],{"intervention":645,"totalTrials":70,"cells":646},"Misoprostol",{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":653,"PHASE4":669,"NA":671},{"trials":648,"activeCount":74},[],{"trials":650,"activeCount":74},[],{"trials":652,"activeCount":74},[],{"trials":654,"activeCount":74},[655],{"nctId":656,"briefTitle":657,"status":254,"phases":658,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":668},"NCT02202967","Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs",[65],"2017-10-11","2016-01-07",104,[663,664,665,666,667],"Chronic Arthritis","Ischemic Heart Disease","Atrial Fibrillation","Anemia","Bleeding",[645],{"trials":670,"activeCount":74},[],{"trials":672,"activeCount":74},[],{"intervention":674,"totalTrials":70,"cells":675},"Dapagliflozin 10 MG Oral",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":695,"NA":697},{"trials":677,"activeCount":74},[],{"trials":679,"activeCount":74},[],{"trials":681,"activeCount":74},[],{"trials":683,"activeCount":74},[684],{"nctId":685,"briefTitle":686,"status":241,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":693},"NCT04860011","DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance",[65],"2022-10-30","2023-04-03","2021-04-27",61,[15],[674,694],"Metolazone",{"trials":696,"activeCount":74},[],{"trials":698,"activeCount":74},[],{"intervention":694,"totalTrials":70,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":713,"NA":715},{"trials":702,"activeCount":74},[],{"trials":704,"activeCount":74},[],{"trials":706,"activeCount":74},[],{"trials":708,"activeCount":74},[709],{"nctId":685,"briefTitle":686,"status":241,"phases":710,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":711,"interventions":712},[65],[15],[674,694],{"trials":714,"activeCount":74},[],{"trials":716,"activeCount":74},[],{"intervention":718,"totalTrials":117,"cells":719},"Alteplase",{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":721,"activeCount":74},[],{"trials":723,"activeCount":74},[],{"trials":725,"activeCount":74},[726,736],{"nctId":727,"briefTitle":728,"status":254,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":735},"NCT02257294","A Trial of Low-dose Adjunctive alTeplase During prIMary PCI",[64],"2018-07","2019-05-08","2016-03",440,[247],[718],{"nctId":737,"briefTitle":738,"status":254,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"enrollment":661,"conditions":742,"interventions":743},"NCT01472926","Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST)",[64],"2013-12-10","2011-12",[18],[744,745],"Tenecteplase","alteplase",{"trials":747,"activeCount":74},[],{"trials":749,"activeCount":74},[],{"trials":751,"activeCount":74},[],{"intervention":753,"totalTrials":70,"cells":754},"Eculizumab",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":756,"activeCount":74},[],{"trials":758,"activeCount":74},[],{"trials":760,"activeCount":74},[761],{"nctId":762,"briefTitle":763,"status":241,"phases":764,"primaryCompletion":765,"completion":732,"start":766,"enrollment":767,"conditions":768,"interventions":770},"NCT02029378","Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study",[64],"2015-10","2014-09",30,[769],"Gullian Barre Syndrome",[753],{"trials":772,"activeCount":74},[],{"trials":774,"activeCount":74},[],{"trials":776,"activeCount":74},[],{"intervention":778,"totalTrials":70,"cells":779},"ABL-101",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":781,"activeCount":74},[],{"trials":783,"activeCount":74},[],{"trials":785,"activeCount":74},[786],{"nctId":787,"briefTitle":788,"status":241,"phases":789,"primaryCompletion":790,"completion":524,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT03463551","Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic",[64],"2019-09","2018-09",18,[794],"Acute Ischaemic Stroke",[778],{"trials":797,"activeCount":74},[],{"trials":799,"activeCount":74},[],{"trials":801,"activeCount":74},[],{"intervention":532,"totalTrials":70,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":805,"activeCount":74},[],{"trials":807,"activeCount":74},[],{"trials":809,"activeCount":74},[810],{"nctId":521,"briefTitle":522,"status":241,"phases":811,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":812,"interventions":813},[64],[529,530],[532,533,534,535,512,536],{"trials":815,"activeCount":74},[],{"trials":817,"activeCount":74},[],{"trials":819,"activeCount":74},[],{"intervention":533,"totalTrials":70,"cells":821},{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":823,"activeCount":74},[],{"trials":825,"activeCount":74},[],{"trials":827,"activeCount":74},[828],{"nctId":521,"briefTitle":522,"status":241,"phases":829,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":830,"interventions":831},[64],[529,530],[532,533,534,535,512,536],{"trials":833,"activeCount":74},[],{"trials":835,"activeCount":74},[],{"trials":837,"activeCount":74},[],{"intervention":534,"totalTrials":70,"cells":839},{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":850,"PHASE4":852,"NA":854},{"trials":841,"activeCount":74},[],{"trials":843,"activeCount":74},[],{"trials":845,"activeCount":74},[846],{"nctId":521,"briefTitle":522,"status":241,"phases":847,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":848,"interventions":849},[64],[529,530],[532,533,534,535,512,536],{"trials":851,"activeCount":74},[],{"trials":853,"activeCount":74},[],{"trials":855,"activeCount":74},[],{"intervention":535,"totalTrials":70,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":859,"activeCount":74},[],{"trials":861,"activeCount":74},[],{"trials":863,"activeCount":74},[864],{"nctId":521,"briefTitle":522,"status":241,"phases":865,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":866,"interventions":867},[64],[529,530],[532,533,534,535,512,536],{"trials":869,"activeCount":74},[],{"trials":871,"activeCount":74},[],{"trials":873,"activeCount":74},[],{"intervention":536,"totalTrials":70,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":877,"activeCount":74},[],{"trials":879,"activeCount":74},[],{"trials":881,"activeCount":74},[882],{"nctId":521,"briefTitle":522,"status":241,"phases":883,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":884,"interventions":885},[64],[529,530],[532,533,534,535,512,536],{"trials":887,"activeCount":74},[],{"trials":889,"activeCount":74},[],{"trials":891,"activeCount":74},[],{"intervention":744,"totalTrials":70,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":904,"PHASE4":906,"NA":908},{"trials":895,"activeCount":74},[],{"trials":897,"activeCount":74},[],{"trials":899,"activeCount":74},[900],{"nctId":737,"briefTitle":738,"status":254,"phases":901,"primaryCompletion":740,"completion":740,"start":741,"enrollment":661,"conditions":902,"interventions":903},[64],[18],[744,745],{"trials":905,"activeCount":74},[],{"trials":907,"activeCount":74},[],{"trials":909,"activeCount":74},[],{"intervention":911,"totalTrials":70,"cells":912},"Bisoprolol",{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":914,"activeCount":74},[],{"trials":916,"activeCount":74},[],{"trials":918,"activeCount":74},[919],{"nctId":920,"briefTitle":921,"status":451,"phases":922,"primaryCompletion":923,"completion":924,"start":925,"enrollment":926,"conditions":927,"interventions":928},"NCT00702156","Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease",[64],"2008-02","2008-07","2005-03",27,[15,382],[911],{"trials":930,"activeCount":74},[],{"trials":932,"activeCount":74},[],{"trials":934,"activeCount":74},[],{"intervention":936,"totalTrials":70,"cells":937},"SQIN-Furosemide",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":939,"activeCount":74},[],{"trials":941,"activeCount":74},[],{"trials":943,"activeCount":74},[944],{"nctId":945,"briefTitle":946,"status":254,"phases":947,"primaryCompletion":948,"completion":948,"start":949,"enrollment":106,"conditions":950,"interventions":951},"NCT05419115","Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure",[64],"2026-03-01","2022-11-17",[15],[936],{"trials":953,"activeCount":74},[],{"trials":955,"activeCount":74},[],{"trials":957,"activeCount":74},[],{"intervention":959,"totalTrials":70,"cells":960},"Defactinib",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":962,"activeCount":74},[],{"trials":964,"activeCount":74},[],{"trials":966,"activeCount":74},[967],{"nctId":968,"briefTitle":969,"status":241,"phases":970,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":979},"NCT02758587","Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)",[63,64],"2019-05","2021-12","2017-07-04",59,[976,977,978],"Carcinoma, Non-small-cell Lung","Mesothelioma","Pancreatic Neoplasms",[959,980],"Pembrolizumab",{"trials":982,"activeCount":74},[],{"trials":984,"activeCount":74},[],{"trials":986,"activeCount":74},[],{"intervention":980,"totalTrials":70,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":74},[],{"trials":992,"activeCount":74},[],{"trials":994,"activeCount":74},[995],{"nctId":968,"briefTitle":969,"status":241,"phases":996,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":997,"interventions":998},[63,64],[976,977,978],[959,980],{"trials":1000,"activeCount":74},[],{"trials":1002,"activeCount":74},[],{"trials":1004,"activeCount":74},[],{"intervention":1006,"totalTrials":70,"cells":1007},"Zibotentan",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1009,"activeCount":74},[],{"trials":1011,"activeCount":74},[],{"trials":1013,"activeCount":74},[1014],{"nctId":1015,"briefTitle":1016,"status":254,"phases":1017,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT04097314","Precision Medicine With Zibotentan in Microvascular Angina",[64],"2023-06-08","2019-10-18",225,[1022],"Microvascular Angina",[1006],{"trials":1025,"activeCount":74},[],{"trials":1027,"activeCount":74},[],{"trials":1029,"activeCount":74},[],{"intervention":1031,"totalTrials":117,"cells":1032},"Qutenza",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1043},{"trials":1034,"activeCount":74},[],{"trials":1036,"activeCount":74},[],{"trials":1038,"activeCount":74},[],{"trials":1040,"activeCount":74},[],{"trials":1042,"activeCount":74},[],{"trials":1044,"activeCount":74},[1045,1055],{"nctId":1046,"briefTitle":1047,"status":241,"phases":1048,"primaryCompletion":1049,"completion":1049,"start":1050,"enrollment":223,"conditions":1051,"interventions":1054},"NCT01748422","Qutenza (Topical Capsaicin 8%) for Painful Arteriovenous Fistulae",[],"2017-08","2015-11",[1052,1053],"Neuropathic Pain","Arteriovenous Fistulae",[1031],{"nctId":1056,"briefTitle":1057,"status":241,"phases":1058,"primaryCompletion":1059,"completion":282,"start":1060,"enrollment":767,"conditions":1061,"interventions":1063},"NCT01748435","Pre-emptive Analgesia With Qutenza in Lower Limb Amputation",[],"2014-02","2013-02",[1052,1062],"Lower Limb Amputation",[1031],{"intervention":1065,"totalTrials":70,"cells":1066},"Apremilast 30mg",{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1073,"PHASE4":1075,"NA":1077},{"trials":1068,"activeCount":74},[],{"trials":1070,"activeCount":74},[],{"trials":1072,"activeCount":74},[],{"trials":1074,"activeCount":74},[],{"trials":1076,"activeCount":74},[],{"trials":1078,"activeCount":74},[1079],{"nctId":1080,"briefTitle":1081,"status":254,"phases":1082,"primaryCompletion":1083,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1089},"NCT03399708","Immune Metabolic Associations in Psoriatic Arthritis",[],"2019-10-12","2019-10-25","2017-06-12",60,[1088,137],"Psoriasis",[1065],{"intervention":1091,"totalTrials":70,"cells":1092},"ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1094,"activeCount":74},[],{"trials":1096,"activeCount":74},[],{"trials":1098,"activeCount":74},[],{"trials":1100,"activeCount":74},[],{"trials":1102,"activeCount":74},[],{"trials":1104,"activeCount":74},[1105],{"nctId":1106,"briefTitle":1107,"status":254,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT00292162","Curing Atrial Fibrillation in Heart Failure",[67],"2009-07","2007-01",41,[1113,665],"Chronic Heart Failure",[1091,1115,1116],"Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol","Aldosterone Antagonists - spironolactone",{"intervention":1115,"totalTrials":70,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1129},{"trials":1120,"activeCount":74},[],{"trials":1122,"activeCount":74},[],{"trials":1124,"activeCount":74},[],{"trials":1126,"activeCount":74},[],{"trials":1128,"activeCount":74},[],{"trials":1130,"activeCount":74},[1131],{"nctId":1106,"briefTitle":1107,"status":254,"phases":1132,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1133,"interventions":1134},[67],[1113,665],[1091,1115,1116],{"intervention":1116,"totalTrials":70,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1147},{"trials":1138,"activeCount":74},[],{"trials":1140,"activeCount":74},[],{"trials":1142,"activeCount":74},[],{"trials":1144,"activeCount":74},[],{"trials":1146,"activeCount":74},[],{"trials":1148,"activeCount":74},[1149],{"nctId":1106,"briefTitle":1107,"status":254,"phases":1150,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1151,"interventions":1152},[67],[1113,665],[1091,1115,1116],{"intervention":1154,"totalTrials":70,"cells":1155},"Olumiant",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1157,"activeCount":74},[],{"trials":1159,"activeCount":74},[],{"trials":1161,"activeCount":74},[],{"trials":1163,"activeCount":74},[],{"trials":1165,"activeCount":74},[],{"trials":1167,"activeCount":74},[1168],{"nctId":1169,"briefTitle":1170,"status":254,"phases":1171,"primaryCompletion":1172,"completion":1172,"start":1173,"enrollment":19,"conditions":1174,"interventions":1175},"NCT05112120","Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis",[],"2023-08-03","2021-07-21",[24],[1154],{"intervention":1177,"totalTrials":70,"cells":1178},"Adalimumab",{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1180,"activeCount":74},[],{"trials":1182,"activeCount":74},[],{"trials":1184,"activeCount":74},[],{"trials":1186,"activeCount":74},[],{"trials":1188,"activeCount":74},[],{"trials":1190,"activeCount":74},[1191],{"nctId":1192,"briefTitle":1193,"status":254,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT05090124","Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE",[67],"2024-11-29","2022-11-04",46,[24],[1177],{"intervention":1201,"totalTrials":70,"cells":1202},"Salmonella typhi vaccination",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1204,"activeCount":74},[],{"trials":1206,"activeCount":74},[],{"trials":1208,"activeCount":74},[],{"trials":1210,"activeCount":74},[],{"trials":1212,"activeCount":74},[],{"trials":1214,"activeCount":74},[1215],{"nctId":1216,"briefTitle":1217,"status":241,"phases":1218,"primaryCompletion":1219,"completion":1220,"start":329,"enrollment":223,"conditions":1221,"interventions":1223},"NCT02653235","Impact of Immune Challenge on Triple Network Connectivity in Humans",[67],"2016-09","2017-01",[1222],"Major Depression",[1201],{"intervention":1225,"totalTrials":70,"cells":1226},"Aspirin",{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1235,"NA":1237},{"trials":1228,"activeCount":74},[],{"trials":1230,"activeCount":74},[],{"trials":1232,"activeCount":74},[],{"trials":1234,"activeCount":74},[],{"trials":1236,"activeCount":74},[],{"trials":1238,"activeCount":74},[1239],{"nctId":1240,"briefTitle":1241,"status":241,"phases":1242,"primaryCompletion":1243,"start":1060,"enrollment":1086,"conditions":1244,"interventions":1246},"NCT01786200","Physiological Effects of Altering Cancer-related Inflammation",[67],"2014-12",[1245],"Colon Cancer",[1225,1247],"Ibuprofen",{"intervention":1247,"totalTrials":70,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1251,"activeCount":74},[],{"trials":1253,"activeCount":74},[],{"trials":1255,"activeCount":74},[],{"trials":1257,"activeCount":74},[],{"trials":1259,"activeCount":74},[],{"trials":1261,"activeCount":74},[1262],{"nctId":1240,"briefTitle":1241,"status":241,"phases":1263,"primaryCompletion":1243,"start":1060,"enrollment":1086,"conditions":1264,"interventions":1265},[67],[1245],[1225,1247],{"intervention":1267,"totalTrials":70,"cells":1268},"Intravenous rtPA",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1270,"activeCount":74},[],{"trials":1272,"activeCount":74},[],{"trials":1274,"activeCount":74},[],{"trials":1276,"activeCount":74},[],{"trials":1278,"activeCount":74},[],{"trials":1280,"activeCount":74},[1281],{"nctId":1282,"briefTitle":1283,"status":451,"phases":1284,"primaryCompletion":526,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1289},"NCT01745692","Pragmatic Ischaemic Stroke Thrombectomy Evaluation",[67],"2015-07","2012-12",65,[794],[1267]]